← Back to Search

Antiretroviral

Simple HAART for HIV/AIDS

Phase 4

Waitlist Available

Led By Richard A Elion, MD

Research Sponsored by Clinical Alliance for Research & Education - Infectious Diseases, LLC.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test a new, simpler treatment regimen for HIV/AIDS. The treatment consists of three drugs: abacavir, Reyataz, and Epivir.

Who is the study for?

This trial is for individuals with HIV infection who have lipodystrophy, a condition affecting body fat distribution. Participants must currently be on their first antiretroviral regimen with abacavir/lamivudine and atazanavir boosted by ritonavir, and have a viral load under 50 copies/ml.Check my eligibility

What is being tested?

The SHARE study tests the effectiveness of a simplified HAART (Highly Active Antiretroviral Therapy) regimen using three drugs: Abacavir, Reyataz (atazanavir), and Epivir (lamivudine). It aims to see if this combination can maintain low HIV levels while managing lipodystrophy.See study design

What are the potential side effects?

Potential side effects may include allergic reactions to Abacavir which can be serious, jaundice or rash from Reyataz, and possible digestive issues or blood disorders from Epivir. Side effects vary among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am on my first HIV treatment with Epzicom, Reyataz, and Norvir.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Clinical Alliance for Research & Education - Infectious Diseases, LLC.Lead Sponsor

1 Previous Clinical Trials

6 Total Patients Enrolled

GlaxoSmithKlineIndustry Sponsor

4,751 Previous Clinical Trials

8,067,472 Total Patients Enrolled

Richard A Elion, MDPrincipal InvestigatorWhitman-Walker Clinic

Media Library

Abacavir (Antiretroviral) Clinical Trial Eligibility Overview. Trial Name: NCT00426296 — Phase 4

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: Abacavir Highlights & Side Effects. Trial Name: NCT00426296 — Phase 4

Abacavir (Antiretroviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00426296 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still open to join this research trial?

"While checking clinicaltrials.gov, it was found that enrollment into this medical trial has already closed. It first appeared on the website in August 2006 and had its last update October 2007. Nonetheless, 501 other trials are actively recruiting participants at present time."

Answered by AI